AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
By Claudia Assis
Abbvie, Cerevel deal is 'significant growth opportunity' for AbbVie
AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's "robust" neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.
Under the terms of the deal, AbbVie will acquire all shares of Cerevel for $45.00 a share in cash, which values the Cambridge, Mass., neurosciences company at $8.7 billion.
The boards of both companies have approved the transaction, which is expected to close in mid-2024 subject to Cerevel shareholder approval and other usual closing conditions, AbbVie said.
Cerevel's stock (CERE) jumped 14% in extended trading after the news before trading was halted, while shares of AbbVie (ABBV) dropped 1.3%.
Cerevel has multiple medications in clinical-stage and preclinical stages for diseases including schizophrenia and Parkinson's, as well as for mood disorders.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie Chief Executive Richard A. Gonzalez said in a statement.
The companies highlighted a few of Cerevel's medications on late-stage trials, including emraclidine, which they called "a potential best-in-class, next-generation" antipsychotic drug that may be effective in treating schizophrenia and Alzheimer's-related psychosis.
AbbVie said that the deal is expected to add to its adjusted per-share earnings by 2030.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-06-23 1659ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?